Skip to content
Screener

Ardelyx ARDX EPS (Diluted)

EPS (Diluted) at other companies

Amgen logo
AmgenAMGN
$4.37+64.9%
Bausch Health Companies logo
Bausch Health CompaniesBHC
-$3.82-2,287%
Ironwood Pharmaceuticals logo
Ironwood PharmaceuticalsIRWD
$0.31+121%
AbbVie logo
AbbVieABBV
$2.03+290%
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
$0.05+183%
XER
Xeris Biopharma Holdings, Inc.XERS
-$0.18-1,700%

Other financials

Income statement

See full
Revenue$120.9M+23.8%
Gross profit$115.1M+35.0%
Operating income-$12.4M+13.7%
Net income-$16.7M+12.4%

Balance sheet

See full
Cash & equivalents$97.2M+7.9%
Total debt$256.2M+24.0%
Total equity$149.0M+6.8%
Total assets$575.9M+23.4%

Cash flow

See full
Operating cash flow-$6.4M+74.7%
CapEx$13.0K-98.0%
Free cash flow-$6.4M+75.3%

Valuation

See full
Market cap$1.2B-4.0%
Enterprise value$1.36B-0.6%
P/S2.7×-0.6×

Profitability

See full
Gross margin94.4%+9.6pp
Operating margin-25.4%
Net margin-12.4%
FCF margin-40.9%

Returns & leverage

See full
Return on equity-38.6%
Debt / equity1.7×+0.2×
Current ratio3.3×-1.0×

Where this comes from

Reported directly by Ardelyx in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.

The source filing: Ardelyx’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:12 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001437402-26-000044
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Loss before provision for income taxes(16,611)(19,078)(54,208)(59,363)
Provision for income taxes1101118860
Net loss$(16,721)$(19,079)$(54,326)$(60,223)
Net loss per share of common stock - basic and diluted$(0.07)$(0.08)$(0.22)$(0.25)
Shares used in computing net loss per share - basic and diluted248,067,253239,928,570246,967,275239,279,962
Comprehensive loss
Net loss$(16,721)$(19,079)$(54,326)$(60,223)
Unrealized losses on available-for-sale securities(69)(56)(391)(95)

Item 1. Financial Statements (Unaudited)

FAQ

What is Ardelyx's EPS (diluted)?
Ardelyx (ARDX) reported EPS (diluted) of -$0.07 in Q2 2026.
How has Ardelyx's EPS (diluted) changed year-over-year?
Ardelyx's EPS (diluted) increased by 12.5% year-over-year, from -$0.08 to -$0.07.
What is the long-term trend for Ardelyx's EPS (diluted)?
Over 3 years (2021 to 2025), Ardelyx's EPS (diluted) has grown at a -44.5% compound annual growth rate (CAGR), from -$1.52 to -$0.26.
What does EPS (diluted) mean?
Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.

Ask your AI about Ardelyx's eps (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude